跳至主導覽 跳至搜尋 跳過主要內容

Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan

  • Andre F. Carvalho
  • , Chih Wei Hsu
  • , Eduard Vieta
  • , Marco Solmi
  • , Wolfgang Marx
  • , Michael Berk
  • , Chih Sung Liang
  • , Ping Tao Tseng
  • , Liang Jen Wang*
  • *此作品的通信作者
  • Deakin University
  • University of Barcelona
  • University of Ottawa
  • Charité – Universitätsmedizin Berlin
  • Triservice General Hospital Taiwan
  • National Defense Medical University
  • Prospect Clinic for Otorhinolaryngology & Neurology
  • National Sun Yat-sen University
  • Asia University Taiwan

研究成果: 期刊稿件 › 文章 › 同行評審

17 引文 斯高帕斯(Scopus)

摘要

Introduction: This study aimed to estimate all-cause mortality in patients after a first-episode mania (FEM) and examine whether six guideline-recommended medications can reduce mortality. Methods: The cohort included population-based FEM samples and matched controls from Taiwan, spanning 2007 to 2018. The primary outcomes assessed were all-cause/suicide-related mortality, while the secondary outcome focused on mortality associated with pharmacological treatments. We compared mortality in post-FEM patients and age-/sex-matched controls without any diagnosed bipolar disorders and patients with and without psychopharmacological treatment using Cox regression analysis, respectively. Statistics were presented with time-to-event adjusted hazard ratios (AHRs) and 95% confidence intervals (CIs). Results: The study included 54,092 post-FEM patients and 270,460 controls, totaling 2,467,417 person-years of follow-up. Post-FEM patients had higher risks of all-cause mortality (AHR 2.38, 95% CI: 2.31-2.45) and suicide death (10.80, 5.88-19.84) than controls. Lithium (0.62, 0.55-0.70), divalproex (0.89, 0.83-0.95), and aripiprazole (0.81, 0.66-1.00) were associated with reduced all-cause mortality compared to non-users. There were no significant all-cause mortality differences for quetiapine (0.95, 0.89-1.01), risperidone (0.92, 0.82-1.02), and paliperidone (1.24, 0.88-1.76) users. When accounting for drug action onset times in sensitivity analyses, only lithium significantly reduced all-cause mortality (AHR range 0.65-0.72). There were 35 and 16 suicide deaths in post-FEM patients and controls, respectively. No drug had a significant effect on suicide deaths (lithium: 6; divalproex: 7; aripiprazole: 0; quetiapine: 10; risperidone: 4; paliperidone: 1). Conclusion: Post-FEM patients had a higher risk of all-cause/suicide-related mortality, and lithium treatment might reduce all-cause mortality.

原文英語
頁(從 - 到)36-45
頁數10
期刊Psychotherapy and Psychosomatics
卷93
發行號1
早期上線日期09 01 2024
DOIs
出版狀態已出版 - 2024

文獻附註

© 2024 The Author(s). Published by S. Karger AG, Basel.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan」主題。共同形成了獨特的指紋。

引用此